Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 12, 1999, Pages 2909-2917

  Häkkinen, Tomi ^a   Luoma, Jukka S ^a   Hiltunen, Mikko O ^a   Macphee, Colin H ^b   Milliner, Kevin J ^b   Patel, Lisa ^b   Rice, Simon Q ^b   Tew, David G ^b   Karkola, Kari ^c   Ylä Herttuala, Seppo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Universit of Eastern Finland   (Finland)

Author keywords

Atherogenesis; Macrophages; Oxidized LDL; Platelet activating factor; Real time fluorescence polymerase chain reaction

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; MESSENGER RNA; PHOSPHOLIPASE A2;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ENZYME ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

EID: 0343852114     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.12.2909     Document Type: Article

References (47)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
3. 2 activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci U S A. 1985;82:3000-3004.
4. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A. 1987;84:2995-2998.
5. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988;85:2805-2809.
6. Steinbrecher UP, Pritchard PH. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet activating factor acetylhydrolase. J Lipid Res. 1989;30:305-315.
7. Kume N, Cybulsky MI, Gimbrone MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 1992;90:1138-1144.
8. Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. The platelet activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein. Trans Assoc Am Phys. 1993;105: 44-63.
9. Tew DG, Southan C, Rice SQJ, Lawrence MP, Li H, Saul HF, Moores K, Gloger IS, Macphee CH. Purification, properties, sequencing and cloning of a lipoprotein associated, serine dependent phospholipase which is involved in the oxidative modification of low density lipoproteins. Arterioscler Thromb Vasc Biol. 1996;16:591-599.
10. Menschikowski M, Kasper M, Lattke P, Schiering A, Schiefer S, Stockinger H, Jaross W. Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis. 1995;118:173-181.
11. Bobryshev YV, Crozier JA, Lord RSA, Tran D, Jamal TO, Pärsson HN, Scott KF. Expression of secretory group II phospholipase A2 by CD1a positive cells in human atherosclerotic plaques. Atherosclerosis. 1996; 127:283-285.
12. 2 in normal and atherosclerotic arteries. Arterioscler Thromb Vasc Biol. 1997;17:300-309.
13. 2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol. 1997;17: 2257-2263.
14. 2 in atherosclerosis. Atherosclerosis. 1997;132:1-8.
15. McMurray HF, Parthasarathy S, Steinberg, D. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest. 1993;92:1004-1008.
16. Nakano T, Raines EW, Abraham JA, Klagsbrun M, Ross R. Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc Natl Acad Sci U S A. 1994;91:1069-1073.
17. Kume N, Gimbrone MA Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 1994;93:907-911.
18. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low density lipoproteins. Nature. 1990;344:160-162.
19. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Ohta Y, Yasue H. LPC in oxidized LDL elicits vasoconstriction and inhibits endothelium-dependent relaxation. Am J Physiol. 1994;267:H2441-H2449.
20. Tjoelker L, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, Hooper S, Trong HL, Cousens LS, Zimmerman GA, Yamada Y, McIntyre TM, Prescott SM, Gray PW. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 1995;374:549-553.
21. 2 in atherogenesis. Pharmacol Rev Commun. 1996;8:309-315.
22. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM. Oxidatively modified LDL contains phospholipids with platelet activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest. 1995;96:2322-2330.
23. Berliner J, Leitinger N, Watson A, Huber J, Fogelman A, Navab M. Oxidized lipids in atherogenesis: formation, destruction and action. Thromb Haemost. 1997;78:195-199.
24. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, La Du BN, Fogelman AM, Berliner JA. Effect of platelet-activating factor acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95: 774-782.
25. Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: purification and properties. J Biol Chem. 1987;262:4223-4230.
26. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secrete platelet-activating factor acetylhydrolase. J Biol Chem. 1990;265:9682-9687.
27. Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S, Glass CK, Sigal E, Witztum JL, Steinherg D. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Nartl Acad Sci U S A. 1990;87:6959-6963.
28. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation. 1995;92:1355-1374.
29. Häkkinen T, Ylä-Herttuala S. An artifact occurring during combined in situ hybridization and immunocytochemistry analysis due to positive chemography. Biotechniques. 1998;24:730-732.
30. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 1990;10:325-335.
31. 30a. Pulinski W, Ylä-Hertuala S, Rosenfeld ME, Bulter SW, Socher SA, Parthasarathy S, Curtiss KL, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Atherosclerosis. In press.
32. Dennis EA. The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci. 1997;22:1-2.
33. Rice S, Southan C, Boyd H, Terrett J, Macphee CH, Moores K, Gloger I, Tew D. Expression, purification, and characterisation of a human senne dependent phospholipase with high specificity for oxidised phospholipids and platelet activating factor. Biochem J. 1998;330:1309-1315.
34. Luoma JS, Strålin P, Marklund SL, Hiltunen TP, Särkioja T, Ylä-Herttuala S. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1998;18:157-167.
35. Stevenson HC, Millar P, Akiyama Y, Favilla T, Beman JA, Herberman R, Stull H, Thurman G, Maluish A, Oldham R. A system for obtaining large numbers of cryopreserved human monocytes purified by leukapheresis and counter-current centrifugation elutriator. J Immunol Methods. 1983; 62:353-363.
36. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338: 479-487.
37. Markwell MAK, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978;87:206-210.
38. Tsoukatos DC, Arborati M, Liapikos T, Clay KL, Murphy RC, Chapman MJ, Ninio E. Copper-catalyzed oxidation mediates PAF formation in human LDL subspecies: protective role of PAF: acetylhydrolase in dense LDL. Arterioscler Thromb Vasc Biol. 1997;17:3505-3512.
39. Guerra R, Zhao B, Mooser V, Stafforini D, Johnston JM, Cohen JC. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res. 1997;38: 2281-2288.
40. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins: pathophysiology and new therapeutic approaches. Eur Heart J. 1998;19:A24-A30.
41. Karabina SP, Liapikos TA, Grekas G, Goudevenos J, Tselepis AD. Distribution of PAF acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim Biophys Acta. 1994;1213: 34-38.
42. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
43. Portman OW, Alexander M. Lysophosphatidylcholine concentrations and metabolism in aortic intima plus inner media: effect of nutritionally induced atherosclerosis. J Lipid Res. 1969;10:158-165.
44. Keaney JF Jr, Xu A, Cunningham D, Jackson T, Frei B, Vita JA. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J Clin Invest. 1995;95:2520-2529.
45. Liu S-Y, Lu X, Choy S, Dembinski TC, Hatch GM, Mymin D, Shen X, Angel A, Choy PC, Man RYK. Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation. Cardiovasc Res. 1994;28: 1476-1481.
46. Hoff HF, Heideman CL, Gotto AM Jr, Gaubatz JW. Apolipoprotein B retention in the grossly normal and atherosclerotic human aorta. Circ Res. 1977;41:684-690.
47. Ylä-Herttuala S, Solakivi T, Hirvonen J, Laaksonen H, Möttönen M, Pesonen E, Raekallio J, Åkerblom HK, Nikkari T. Glycosaminoglycans and apolipoproteins B and A-I in human aortas: chemical and immunological analysis of lesion-free aortas from children and adults. Arteriosclerosis. 1987;7:333-340.